Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma

European Annals of Allergy and Clinical Immunology

Volumn 37, Issue 8, 2005, Pages 303-308

  Berto, P ^a   Bassi, M ^b   Incorvaia, C ^c   Frati, F ^d,e   Puccinelli, P ^e   Giaquinto, C ^f   Cantarutti, L ^f   Ortolani, Cl ^g  

^a Pbe Consulting   (Italy)

^b RHO HOSPITAL   (Italy)

^c ICP Hospital   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e Scientific Department   (Italy)

^f Pedianet Network   (Italy)

^g Istituto Allergologico Lombardo   (Italy)

Author keywords

Cost analysis; Economic analysis; Outcomes; Sublingual immunotherapy

Indexed keywords

ALLERGEN; STALORAL;

ADOLESCENT; AGE DISTRIBUTION; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG MEGADOSE; ECONOMIC EVALUATION; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; GENDER; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; RESOURCE ALLOCATION;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ALLERGENS; ASTHMA; CHILD; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; RHINITIS, ALLERGIC, SEASONAL;

EID: 27744525043     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. - Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 1998;351:1225-32.
2. Bousquet J., van Cauwenberge P. (eds). - Allergic Rhinitis and its Impact on Asthma (ARIA). Position Paper endorsed by WHO. J Allergy Clin Immunol 2001;108(suppl 5):147-334.
3. Passalacqua G., Lombardi C., Canonica G.-W.. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol. 2004;4(1):31-36.
4. Wilson D.-R., Torres-Lima M., Durham S.-R. - Sublingual immunotherapy for allergic rhinitis. Allergy 2005;60(1):4-12.
5. Reed S., Lee T., McCrory D. - The economic burden of allergic rhinitis. A critical evaluation of the literature. Pharmacoeconomics 2004;22(6):345-361.
6. McMenamin P. - Costs of hay fever in the Unites States in 1990. Ann Allergy 1994;73:35-39.
7. Malone D.-C., Lawson K.-A., Smith D.-H., Arrighi H.-M., Battista C. - A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunology 1997;99:22-27.
8. Law A.-W. - Reed SD, Sundy J Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003;111(2):296-300.
9. Ray N.-F., Baraniuk J.-N., Thamer M., Rinehart C.-S., Gergen P.-J., Kaliner M. - Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103:401-407.
10. Meltzer E.-O. - The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S805-28.
11. Kessler R.-C., Almeida D.-M., Berglund P., Stang P. - Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:289-295.
12. Crystal-Peters J., Crown W.-H., Goetzel R.-Z., Schutt D.-C. - The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000;6:373-378.
13. Ross R.-N. - The costs of allergic rhinitis. Am J Manag Care 1996;2:285-290.
14. Ministero della Sanità. - Nomenclatore Tariffario delle prestazioni ambulatoriali DM 22.7.96 Gazzetta Ufficiale 1996;216.
15. Informatore farmaceutico Roma, 2003, O.E.M.S.
16. Stallergénes, data on file.
17. Lucioni C., Garancini M.-P., Massi-Benedetti M., Mazzi S., Serra G. - II costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. PharmacoEconomics-Italian Research Articles 2000;2(1):1-21.
18. Banca d'Italia. - Proceedings from Assemblea generale ordinaria dei partecipanti, Roma 31 May 2003.
19. Lucioni C., Costa B., Sessa A. - I costi dell'influenza in Italia. Farmeconomia e Percorsi Terapeutici 2001;2(1):11-18.
20. Giaquinto C., Sturkenboom M., Mannino S., Arpinelli F., Nicolosi A., Cantarutti L. - Gruppo di studio sulla varicella in età pediatrica (Pedianet Varicella Study Group) Epidemiology and outcomes of varicella in Italy: results of a prospective study of children (0-14 years old) followed up by pediatricians (Pedianet study). Ann Ig 2002;14(4-S6):21-27.
21. www.ministerosalute.it/programmazione/sdo/ric_informazioni/default.jsp (access of July 15 2004).
22. Büchner K, Siepe M. Nutzen der Hyposensibilisierung unter wirtschaftlichen Aspekten. Allergo J 1995;4:156-163.
23. Kumar P., Kamboj S., Rao P., Cai X., Vedere T., Gupta S. - The cost of care and quality of life in patients with allergic rhinitis on allergen immunotherapy. ACI International 1997;9/5:133-135.
24. Schadlich P.-K., Brecht J.-G. - Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17(1):37-52.